Dear All: Following the precept (often attributed to Osler, but I can’t find it in his Principles and Practice 1892) that the 3 core elements of treatment are “diagnosis, diagnosis, and diagnosis,” FIND (Foundation for Innovative New Diagnostics) is an international non-profit organization that enables the development and delivery of diagnostic tests for poverty-related diseases, including TB, malaria,

Dear All, Three things to share this afternoon. First, Alan Carr has published a newsletter (link) reporting the results from the COVID-19 survey we did as a group last week (go here for the 26 Mar 2020 newsletter about the survey). Approximately 150 individuals in 14 countries responded during 27-29 Mar. Time-to-peak cases was estimated at

Dear All, If you are a US citizen, you have an opportunity right now (as in today/tomorrow) to push for the inclusion of the DISARM Act in the COVID-19 bill(s) currently being circulated in Congress. As a reminder, DISARM is the legislation that would reimburse QIDP antimicrobials in the hospital setting outside of the DRG

Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter): Wonkish and long note alert … top-up your coffee and settle in… We learned about a week ago that Tetraphase, despite having brought an antibacterial (eravacycline) to approval, has been sold for stock worth $14.4m (plus a potential $12.5m more if aggressive sales targets are achieved).

Dear All: Two papers (one with an editorial) that are worth your time. First, we have publication of the long-awaited FNIH (Foundations for the NIH) paper on trial designs for studies of HABP-VABP (Hospital-Associated Bacterial Pneumonia and Ventilator-Associated Pneumonia). The paper also comes with an editorial: Talbot, G. H., A. Das, S. Cush, A. Dane, M.